All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-06-12T15:18:00.000Z

What are the factors guiding treatment decisions for transplantation in MF?

By Claire Baker
Featured
Francesco Passamonti
Jun 12, 2020
Share:

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Francesco Passamonti, University of Insubria, Varese, IT. We asked: What are the factors guiding treatment decisions for transplantation in myelofibrosis?

There have been a number of different models designed to assist treatment decisions in myelofibrosis. Here, Francesco Passamonti outlines these parameters and how they are used in clinical practice to determine those patients put forward for stem cell transplant. Major considerations include the probability of survival and non-relapse mortality.

What are the factors guiding treatment decisions for transplantation in MF?

More about...
EHA 2020Myeloproliferative neoplasmsPrimary myelofibrosis

Related articles

Add bookmark

Long-term safety analyses of momelotinib in patients with myelofibrosis

Momelotinib is a selective and orally available inhibitor of Janus kinase (JAK) 1, JAK2, and activin A type 1 receptor (ACVR1) that targets key drivers of myelofibrosis. The...

Jun 19, 2020
Add bookmark

Long-term safety analyses of momelotinib in patients with myelofibrosis

Momelotinib is a selective and orally available inhibitor of Janus kinase (JAK) 1, JAK2, and activin A type 1 receptor (ACVR1)...

Jun 19, 2020
Add bookmark

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

Interview with John Mascarenhas, Icahn School of Medicine at Mount Sinai during the 25th Congress of the European Hematology Association (EHA). We asked: Does the...

Jun 18, 2020
Add bookmark

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

Interview with John Mascarenhas, Icahn School of Medicine at Mount Sinai during the 25th Congress of the European...

Jun 18, 2020

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox